Análise da eficácia e segurança da monoterapia com revumenibe em pacientes com leucemia aguda relapsada/refratária com rearranjo KMT2A

Referência

1. Aldoss, Ibrahim, et al. Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study. American Society of hematology: Annual Meeting and Exposition. 2023. Disponível em: .https://ash.confex.com/ash/2023/webprogram/Paper192042.html